The U.S. Food and Drug Administration (FDA) approved Hemgenix (etranacogene dezaparvovec), gene therapy for the treatment of adults with hemophilia B (congenital factor 9 deficiency) who currently use factor 9 prophylaxis therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes.